Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | 이지희 | * |
| dc.contributor.author | 김희선 | * |
| dc.date.accessioned | 2025-08-07T07:11:19Z | - |
| dc.date.available | 2025-08-07T07:11:19Z | - |
| dc.date.issued | 2025 | * |
| dc.identifier.issn | 1873-2968 | * |
| dc.identifier.other | OAK-37504 | * |
| dc.identifier.uri | https://dspace.ewha.ac.kr/handle/2015.oak/272187 | - |
| dc.description.abstract | Necroptosis is involved in neuronal cell death and inflammation, with the receptor-interacting protein kinase (RIPK) 1-RIPK3-mixed lineage kinase domain-like protein (MLKL) necrosome complex playing a significant role. Although MLKL is considered the final executor of necroptosis, its role in neuroinflammation remains unclear. In the present study, we explored the role of MLKL in lipopolysaccharide (LPS)- or polyinosinic-polycytidylic acid (poly(I:C))-induced neuroinflammation using the MLKL-specific inhibitor necrosulfonamide (NSA). NSA or MLKL siRNA reduced nitric oxide and proinflammatory cytokine production under LPS- or poly(I:C)-induced inflammation and LPS/QVD/BV6- or poly(I:C)/QVD/BV6-induced necroptosis in BV2 microglial cells; QVD is a pan-caspase inhibitor, and BV6 antagonizes inhibitor of apoptosis protein. Additionally, NSA suppressed the phosphorylation of RIPK1-RIPK3-MLKL and reduced the expression of damage-associated molecular patterns, including high mobility group box 1, in inflammatory/necroptotic BV2 cells. Subsequent mechanistic studies revealed that NSA reduces inflammation by upregulating nuclear factor-erythroid 2 (NF-E2)-related factor (Nrf2) signaling pathways and blocking reactive oxygen species, mitogen-activated protein kinases, and nuclear factor-κB. The anti-inflammatory effects of NSA were confirmed in the brains of mice with systemic inflammation caused by LPS or poly(I:C) injection. NSA suppressed microglial activation, proinflammatory gene expression, and disruption of blood–brain barrier integrity while upregulating Nrf2-mediated antioxidant enzymes in the brains of LPS- or poly(I:C)-injected mice. Furthermore, NSA suppressed the phosphorylation and expression of RIPK1-RIPK3-MLKL, and p-MLKL expressed in activated microglia, indicating that MLKL plays a crucial role in microglial activation in mice with systemic inflammation. Therefore, modulating MLKL expression may be an effective treatment for necroptosis-related neuroinflammatory disorders. © 2025 Elsevier B.V., All rights reserved. | * |
| dc.language | English | * |
| dc.publisher | Elsevier Inc. | * |
| dc.subject | Microglia | * |
| dc.subject | Mlkl | * |
| dc.subject | Necroptosis | * |
| dc.subject | Necrosulfonamide | * |
| dc.subject | Neuroinflammation | * |
| dc.subject | Systemic Inflammation | * |
| dc.subject | Catalase | * |
| dc.subject | Gelatinase B | * |
| dc.subject | Inducible Nitric Oxide Synthase | * |
| dc.subject | Lactate Dehydrogenase | * |
| dc.subject | Lactate Dehydrogenase A | * |
| dc.subject | Mitogen Activated Protein Kinase | * |
| dc.subject | Neutrophil Collagenase | * |
| dc.subject | Nitric Oxide | * |
| dc.subject | Occludin | * |
| dc.subject | Polyinosinic Polycytidylic Acid | * |
| dc.subject | Protein Kinase | * |
| dc.subject | Protein Serine Threonine Kinase | * |
| dc.subject | Stromelysin | * |
| dc.subject | Toll Like Receptor 2 | * |
| dc.subject | Toll Like Receptor 4 | * |
| dc.subject | Acrylamides | * |
| dc.subject | Anti-inflammatory Agents | * |
| dc.subject | Lipopolysaccharides | * |
| dc.subject | Mlkl Protein, Mouse | * |
| dc.subject | N-(4-(n-(3-methoxypyrazin-2-yl)sulfamoyl)phenyl)-3-(5-nitrothiophene-2-yl)acrylamide | * |
| dc.subject | Poly I-c | * |
| dc.subject | Protein Kinases | * |
| dc.subject | Sulfonamides | * |
| dc.subject | Antiinflammatory Agent | * |
| dc.subject | Claudin 5 | * |
| dc.subject | Cyclooxygenase 2 | * |
| dc.subject | Glycoprotein Gp 91 | * |
| dc.subject | Heme Oxygenase 1 | * |
| dc.subject | High Mobility Group B1 Protein | * |
| dc.subject | Immunoglobulin Enhancer Binding Protein | * |
| dc.subject | Interleukin 1alpha | * |
| dc.subject | Interleukin 1beta | * |
| dc.subject | Interleukin 33 | * |
| dc.subject | Interleukin 6 | * |
| dc.subject | Messenger Rna | * |
| dc.subject | Mitogen Activated Protein Kinase P38 | * |
| dc.subject | Mixed Lineage Kinase Domain Like Protein | * |
| dc.subject | Protein P22 | * |
| dc.subject | Protein P47 | * |
| dc.subject | Protein P67 | * |
| dc.subject | Protein Serine Threonine Kinase Inhibitor | * |
| dc.subject | Reactive Oxygen Metabolite | * |
| dc.subject | Receptor Interacting Protein Kinase 1 | * |
| dc.subject | Receptor Interacting Protein Kinase 3 | * |
| dc.subject | Small Interfering Rna | * |
| dc.subject | Toll Like Receptor 3 | * |
| dc.subject | Transcription Factor Nrf2 | * |
| dc.subject | Transcription Factor Rela | * |
| dc.subject | Unclassified Drug | * |
| dc.subject | Acrylamide Derivative | * |
| dc.subject | Lipopolysaccharide | * |
| dc.subject | Sulfonamide | * |
| dc.subject | Animal Cell | * |
| dc.subject | Animal Experiment | * |
| dc.subject | Animal Model | * |
| dc.subject | Animal Tissue | * |
| dc.subject | Antiinflammatory Activity | * |
| dc.subject | Article | * |
| dc.subject | Brain Tissue | * |
| dc.subject | Bv-2 Cell Line | * |
| dc.subject | Controlled Study | * |
| dc.subject | Cytokine Production | * |
| dc.subject | Enzyme Phosphorylation | * |
| dc.subject | Female | * |
| dc.subject | Gel Mobility Shift Assay | * |
| dc.subject | Gene Expression | * |
| dc.subject | Immunofluorescence | * |
| dc.subject | Immunohistochemistry | * |
| dc.subject | Lipopolysaccharide-induced Neuroinflammation | * |
| dc.subject | Male | * |
| dc.subject | Mouse | * |
| dc.subject | Nervous System Inflammation | * |
| dc.subject | Nonhuman | * |
| dc.subject | Nrf2 Signaling | * |
| dc.subject | Real Time Polymerase Chain Reaction | * |
| dc.subject | Reverse Transcription Polymerase Chain Reaction | * |
| dc.subject | Signal Transduction | * |
| dc.subject | Upregulation | * |
| dc.subject | Western Blotting | * |
| dc.subject | Animal | * |
| dc.subject | C57bl Mouse | * |
| dc.subject | Cell Line | * |
| dc.subject | Dose Response | * |
| dc.subject | Drug Effect | * |
| dc.subject | Drug Therapy | * |
| dc.subject | Genetics | * |
| dc.subject | Metabolism | * |
| dc.subject | Physiology | * |
| dc.subject | Animals | * |
| dc.subject | Dose-response Relationship, Drug | * |
| dc.subject | Mice | * |
| dc.subject | Mice, Inbred C57bl | * |
| dc.subject | Neuroinflammatory Diseases | * |
| dc.title | Anti-inflammatory mechanism of the MLKL inhibitor necrosulfonamide in LPS- or poly(I:C)-induced neuroinflammation and necroptosis | * |
| dc.type | Article | * |
| dc.relation.volume | 239 | * |
| dc.relation.index | SCIE | * |
| dc.relation.index | SCOPUS | * |
| dc.relation.journaltitle | Biochemical Pharmacology | * |
| dc.identifier.doi | 10.1016/j.bcp.2025.117021 | * |
| dc.identifier.wosid | WOS:001508976400002 | * |
| dc.identifier.scopusid | 2-s2.0-105007518087 | * |
| dc.author.google | Kim D. | * |
| dc.author.google | Leem Y. | * |
| dc.author.google | Park J.S. | * |
| dc.author.google | Kim S. | * |
| dc.author.google | Choi Y. | * |
| dc.author.google | Kang J.L. | * |
| dc.author.google | Kim H. | * |
| dc.contributor.scopusid | 이지희(7404517577) | * |
| dc.contributor.scopusid | 김희선(57191372551) | * |
| dc.date.modifydate | 20261006122233 | * |